Gynecological cancer is a term utilized for a wide range of cancer that can happen in or on a lady's conceptive organs and privates. This incorporates cancers of the vagina, vulva, ovaries, uterus, cervix, and fallopian tubes. Each gynecologic cancer has its own signs and manifestations. Cancer is always named for the part of the body where it starts. Gynecologic cancers begin in different places within a woman’s pelvis, which is the area below the stomach and in between the hip bones. Thus, with the increasing prevalence of gynecological cancer worldwide, the demand for gynecological cancer drugs is also increasing with a rapid pace, driving the growth of the gynecological cancer drugs market.
According to the American Society of Clinical Oncology (ASCO), in 2021, approximately 66,570 people in the United States are expected to be diagnosed with uterine, or endometrial, cancer. Uterine cancer is the fourth most common cancer for women in the U.S. Thus, there is an increasing demand for Gynecological cancer drugs market in the region. In April 2021, the Food and Drug Administration (FDA) granted accelerated approval to Jemperli (dostarlimab) to treat patients with recurrent or advanced endometrial cancer. Jemperli helps to fight against cancer cells by blocking the cellular pathway known as PD-1/PD-L1. Around 75% of uterine cancers are diagnosed at an early stage and are typically curable with surgery.
Moreover, in June 2018, the FDA approved pembrolizumab (Keytruda, Merck) to treat patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. This in turn is expected to augment the growth of the gynecological cancer drugs market, especially in the U.S. Furthermore, several factors, such as late start of menopause, early start of menstruation, mutations, obesity, infertility, and Human Papillomavirus are responsible for the occurrence of gynecological cancer. Thus, there is an increasing demand for gynecological cancer drugs.
Gynecological cancer can be treated with surgeries, therapies, various drugs, or chemotherapy. Treatment depends on the type, stage, and severity of the cancer. However, each gynecologic cancer is unique, with different signs and symptoms, risk factors, and prevention strategies. Thus, there is high demand for gynecological cancer drugs to treat all types of gynecological cancer, driving the gynecological cancer drugs market growth. However, threat of failure, high cost of drug development, and adverse effects of drugs are expected to restrain the growth of the gynecological cancer drugs market.
